Skip to content

aTyr Pharma ATYR Income Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$190K0.0%$190K$0$0-100%
$55.72M-7.5%$60.22M-2.2%$61.56M+13.5%$54.23M+2.7%$52.82M-2.9%
$17.76M+0.9%$17.6M+1.8%$17.29M+9.3%$15.82M+11.2%$14.23M+3.3%
$73.48M-5.6%$77.82M-1.3%$78.84M+12.6%$70.05M+4.5%$67.05M-1.6%
-$73.29M+5.6%-$77.63M+1.3%-$78.65M-12.3%-$70.05M-4.5%-$67.05M+1.3%
$3.26M-7.1%$3.5M-0.6%$3.52M+3.4%$3.41M-6.3%$3.64M-6.6%
-$70.03M+5.5%-$74.12M+1.3%-$75.12M-12.7%-$66.64M-5.1%-$63.41M+1.0%
-$0.73+7.6%-$0.79+3.7%-$0.82-3.8%-$0.79+1.3%-$0.80+7.0%
-$72.63M+5.6%-$76.96M+1.3%-$77.98M-12.4%-$69.36M-4.5%-$66.35M+1.3%
-$73.29M+5.6%-$77.63M+1.3%-$78.65M-12.3%-$70.05M-4.5%-$67.05M+1.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is aTyr Pharma's revenue?
aTyr Pharma (ATYR) generated $190.0K in revenue over the trailing twelve months, down 19.1% year over year.
Is aTyr Pharma profitable?
aTyr Pharma is not currently profitable: it reported a net loss of $70.0M over the trailing twelve months, a -39009.5% net margin.
What is aTyr Pharma's earnings per share?
aTyr Pharma's diluted EPS over the trailing twelve months is $-0.73.
Where does aTyr Pharma's income statement data come from?
Every line is extracted from aTyr Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.